JPMorgan Bullish on BSE, HSBC Upgrades Lenskart and Nykaa, While Citi Flags

Dalal Street desks are closely tracking sharp adjustments across leading institutional portfolios on Thursday, November 5, 2026, as premier domestic and global brokerage houses rolled out crucial rating revisions and price targets on prominent market movers including BSE, Nykaa, Lenskart, Aurobindo Pharma, Dabur India, and Tata Motors CV. Leading exchange operator BSE found itself at the center of divergent institutional opinions following its robust second-quarter financial print. While Bernstein reaffirmed an "underperform" stance on BSE—even as it lifted its target price to ₹3,180 on the back of resilient cash volume trends and broader market-share gains—the research firm cautioned that market share expansion could be approaching an operational ceiling, making rapid trajectory continuation difficult to sustain. Conversely, JPMorgan maintained an aggressive "overweight" rating with a street-high target price of ₹3,960, spotlighting BSE’s 34.1 percent year-on-year revenue expansion and a notable 45.7 percent jump in net profit to ₹783 crore (excluding its CDSL stake divestment), largely propelled by core transactional strength and supporting other income.

Retail and Consumer Momentum: HSBC Upgrades Lenskart to Buy and Lifts Nykaa Target

Consumer-facing digital and retail powerhouses received notable validation from HSBC, which took an optimistic stance on both FSN E-Commerce Ventures (Nykaa) and eyewear major Lenskart. Retaining a high-conviction "buy" rating on Nykaa, HSBC elevated its price target to ₹410 per share, citing well-rounded momentum across the platform's core verticals where beauty and personal care (BPC) expanded by 25 percent and the fashion vertical accelerated by 42 percent. Bolstered by the expansion of its proprietary House of Brands and an EBITDA margin improvement of roughly 1.96 percentage points year-on-year—marking the company's fourth consecutive quarter of widening margins—HSBC upwardly revised its fiscal 2027 operational EBITDA forecast by approximately 3 percent. Simultaneously, the brokerage upgraded Lenskart from "hold" to "buy" and raised its target price to ₹790, citing a 3 percent beat in second-quarter EBITDA alongside robust 21 percent same-store sales growth (SSSG) in India and 23 percent constant-currency expansion across overseas markets, creating a compelling runway for margin improvements.

FMCG, Pharma, and Commercial Vehicles: Divergence on Dabur, Citi Cautious on Aurobindo, and Nomura Backs Tata Motors CV

The FMCG and pharmaceutical spaces reflected contrasting tactical strategies, particularly around Dabur India in the wake of executive leadership changes. While Jefferies retained a "buy" rating on Dabur with a trimmed target price of ₹535—praising resilient domestic volumes, international operational stability, and core momentum across foods and personal care despite rising operating costs and healthcare regulatory drags—Citi initiated a starkly contrasting "sell" recommendation with a target price of ₹380. Even though Dabur posted a 12 percent top-line expansion, 8 percent EBITDA growth, and an 11 percent increase in net profit with premium portfolios accounting for 20 percent of domestic receipts, Citi flagged uncertainties regarding the company's forward strategic direction as Chief Executive Officer Mohit Malhotra prepares to demit office on November 13. In the healthcare basket, Citi reiterated a "sell" rating on Aurobindo Pharma with a ₹1,270 target price; despite stronger-than-expected Q2 operational metrics driven by a 19 percent constant-currency surge in Europe and a 20 percent sequential bump in US turnover to $477 million through the Lannett integration, the firm flagged intensifying European pricing pressures. Meanwhile, Japanese brokerage Nomura issued a "buy" call on Tata Motors' commercial vehicle business with a target price of ₹511, acknowledging that while partner Iveco's industrial margins tumbled to zero in the third quarter from 2.8 percent in Q2 amid near-term macro headwinds, internal operational enhancements and strategic supply recalibrations position the commercial carrier division for sustainable medium-term recovery.